Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Lieber, André  [Clear All Filters]
2023
Wang H, Georgakopoulou A, Zhang W, Kim J, Gil S, Ehrhardt A, Lieber A. HDAd6/35++ - A new helper-dependent adenovirus vector platform for transduction of hematopoietic stem cells. Mol Ther Methods Clin Dev. 2023;29:213-226.
Li C, Georgakopoulou A, Newby GA, Chen PJ, Everette KA, Paschoudi K, Vlachaki E, Gil S, Anderson AK, Koob T, et al. In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model. Blood. 2023.
2021
Li C, Goncalves KA, Raskó T, Pande A, Gil S, Liu Z, Izsvák Z, Papayannopoulou T, Davis JC, Kiem H-P, et al. Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice. Blood Adv. 2021;5(5):1239-1249.
2020
Li C, Wang H, Georgakopoulou A, Gil S, Yannaki E, Lieber A. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model. Mol Ther. 2020.
2019
Wang H, Liu Z, Li C, Gil S, Papayannopoulou T, Doering CB, Lieber A. High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells. Blood Adv. 2019;3(19):2883-2894.
2018
Wang H, Georgakopoulou A, Psatha N, Li C, Capsali C, Samal HBhusan, Anagnostopoulos A, Ehrhardt A, Izsvák Z, Papayannopoulou T, et al. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia. J Clin Invest. 2018.
2016
Saydaminova K, Strauss R, Xie M, Bartek J, Richter M, van Rensburg R, Drescher C, Ehrhardt A, Ding S, Lieber A. Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells. Cancer Biol Ther. 2016.
2013
Choi I-K, Strauss R, Richter M, Yun C-O, Lieber A. Strategies to increase drug penetration in solid tumors. Front Oncol. 2013;3:193.